Nonpeptide SSTR5 Agonists for Injection-Free Hormone Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current somatostatin peptide analogs for treating conditions like GH-secreting adenomas and pancreatic neuroendocrine tumors are expensive and require frequent painful injections, while there are no specific drugs for congenital hyperinsulinism, a condition causing abnormally high insulin levels leading to hypoglycemia.
Innovation Solution
Development of non-peptide somatostatin modulators that selectively activate the SSTR5 receptor to inhibit insulin secretion and promote glucose release, offering a structurally different approach to hormone regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If somatostatin peptide analogs (octreotide, lanreotide, pasireotide) are used as depot injections, then hormone levels can be normalized for treating GH-secreting adenomas and pancreatic neuroendocrine tumors, but the treatment becomes extremely expensive and requires frequent painful injections that cause injection site reactions
Solution Approach 1:
The patent changes the chemical structure parameter from peptide-based to non-peptide small molecule structure, which fundamentally alters the pharmacokinetic properties. This structural transformation enables oral bioavailability and longer half-life, eliminating the need for frequent injections while maintaining therapeutic efficacy in normalizing hormone levels
Solution Approach 2:
The patent replaces the mechanical injection delivery system with an oral administration system. By developing orally bioavailable non-peptide compounds, the treatment transitions from parenteral (injection) to enteral (oral) route, eliminating injection-related pain and site reactions while maintaining therapeutic reliability
2Reliability
If peptide analogs are used for treatment, then hormone regulation can be achieved, but the treatment cost becomes extremely high
Solution Approach 1:
The patent changes the molecular class parameter from complex peptide structures to simpler non-peptide small molecules. This structural simplification reduces manufacturing complexity and production costs while maintaining the ability to regulate hormone levels effectively, making the treatment more cost-effective
3Ease of operation
If non-peptide somatostatin modulators are developed, then treatment cost and injection burden are reduced, but selective activation of SSTR5 receptor must be achieved to minimize side effects
Solution Approach 1:
The patent applies local quality by designing the non-peptide compound with specific molecular features that confer selective affinity for the SSTR5 receptor subtype. The chemical structure is optimized to interact preferentially with SSTR5 binding sites, enabling selective activation that minimizes off-target effects on other somatostatin receptor subtypes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide a cost-effective and less invasive treatment option for conditions like hyperinsulinism and neuroendocrine tumors, reducing the need for frequent injections and minimizing side effects by selectively modulating somatostatin receptor activity.
Implementation Method 1
compounds described herein selectively activate somatostatin receptor subtype 5 (SSTR5) that in turn inhibits insulin secretion and promotes glucose release
Data Source
AI summary
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.